CIBC Private Wealth Group’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

CIBC Private Wealth Group’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,166	Closed	-$81K	–	607
2020 Q1	$81K	Hold	1,166	–	–	﹤0.01%	821
2019 Q4	$75K	Hold	1,166	–	–	﹤0.01%	885
2019 Q3	$68K	Hold	1,166	–	–	﹤0.01%	876
2019 Q2	$69K	Sell	1,166 -3,333	-74%	-$194K	﹤0.01%	904
2019 Q1	$293K	Buy	4,499 +3,499	+350%	+$199K	﹤0.01%	827
2018 Q4	$53K	Hold	1,000	–	–	﹤0.01%	853
2018 Q3	$57K	Hold	1,000	–	–	﹤0.01%	947
2018 Q2	$59K	Buy	+1,000	New	+$58.8K	﹤0.01%	1132
2017 Q4	–	Sell	-3,333	Closed	-$206K	–	1925
2017 Q3	$206K	Buy	+3,333	New	+$216K	﹤0.01%	897

Other funds holding BCLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

AHB

Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

CIBC Private Wealth Group's BCLI Position: Q2 2020 in Review

CIBC Private Wealth Group sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2020, closing a stake of 1,166 shares — an estimated $81K sold.

CIBC Private Wealth Group first reported a position in BCLI in Q3 2017 and held it in 9 quarters. The position peaked at $293K in Q1 2019. 76 funds tracked by Wall St. Rank hold BCLI as of Q2 2020.

CIBC Private Wealth Group reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2020 after selling out during the quarter.
CIBC Private Wealth Group sold 1,166 BRAINSTORM CELL THERAPUTC shares in Q2 2020, an estimated $81K.
CIBC Private Wealth Group first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2017 and held it in 9 quarters.
CIBC Private Wealth Group's BRAINSTORM CELL THERAPUTC position peaked at $293K in Q1 2019.
76 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2020.

Based on CIBC Private Wealth Group's 13F filing for Q2 2020, filed 13 Aug 2020.